Newsletter | November 23, 2022

11.23.22 -- Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising

Featured Articles
Are You Really Fostering A Truly Inclusive Environment?

As business leaders, we are called on now more than ever to make sure our workplaces are truly welcoming to talented people, irrespective of their background or gender identity.

Fueling A Focused Drug Development Model

Privately held Debiopharm is laser-focused on oncology and infectious diseases, with a business model that strategically avoids drug discovery on one end and commercialization on the other.

Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising

The CEO Of Aristea talks about the company’s unusual move to do both a Series B round, but not as a crossover, while also making a deal with another pharma company.

Web-Exclusive Content
“Risky Business:” How Cell & Gene Therapies Are Upending Partnership Models

This article is the final installment of a three-part series examining how advanced therapy scientific and quality expectations are impacting outsourcing business practices/models today and, hopefully, creating a foundation for greater risk-sharing in the future.

Industry Insights
Off-The-Shelf Vs. Novel Devices: Selecting A Drug Delivery System

Whether bringing a novel therapy to market or altering current devices for life cycle management, companies must determine the best selection for administration without affecting drug efficacy, quality, and safety.

Digital Edition
November 2022 Digital Edition

Inside you will find more on:

  • Pet Health Drug Development
  • Fundraising
  • CEO Corner
  • Diversity In Clinical Trials

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable?  Read these guidelines first before submitting your idea or your article to our editorial director.